Chemotherapy Induced Diarrhea Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Egetis Therapeutics, MediciNova, Sonnet Biotherapeutics, MakScientific, MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceu

DelveInsight's "Chemotherapy Induced Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Chemotherapy Induced Peripheral Neuropathy, historical and forecasted epidemiology as well as the Chemotherapy Induced Peripheral Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Discover Key Insights into the Chemotherapy-induced Peripheral Neuropathy Market with DelveInsight's In-Depth Report @ Chemotherapy-induced Peripheral Neuropathy Market Size- https://www.delveinsight.com/sample-request/cipn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Chemotherapy Induced Peripheral Neuropathy Market Report
• In February 2025, Dogwood Therapeutics Inc. initiated a randomized study to assess the safety and efficacy of a single subcutaneous (SC) administration of HAL treatment in patients with CINP.
• In February 2025, Eli Lilly and Company launched a study to evaluate the safety and effectiveness of a treatment compared to a placebo in individuals with nerve pain that starts in the feet and progresses up the leg to just below the knee. The United States showed the highest Chemotherapy Induced Peripheral Neuropathy Incident Population accounting for approximately 41% of total cases in the 7MM.
• As per DelveInsight's estimates, the overall incidence of moderate CIPN was maximum, followed by mild and then severe, and is subjected to increase rapidly in the coming years.
• In the US, ~93,000 breast cancer patients developed CIPN, whereas other types of cancer (excluding lung, colorectal, pancreatic, and multiple myeloma cancer) patients represented more than 450,000 cases of CIPN.
• Among EU4 and the UK, Germany had the highest incident population in 2023, accounting for ~28% of the total incident population of CIPN.
• The leading Chemotherapy Induced Peripheral Neuropathy companies such as Egetis Therapeutics, MediciNova, Sonnet Biotherapeutics, MakScientific, MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma, Enveric Biosciences, Regenacy Pharmaceuticals, NeuroBo Pharmaceuticals and others.
• Promising Chemotherapy Induced Peripheral Neuropathy Therapies such as PledOx, Ibudilast, SON 080, AM 1710 and others.

Stay ahead in the Chemotherapy-induced Peripheral Neuropathy Therapeutics Market with DelveInsight's Strategic Report @ Chemotherapy-induced Peripheral Neuropathy Market Outlook- https://www.delveinsight.com/sample-request/cipn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chemotherapy-induced Peripheral Neuropathy Epidemiology Segmentation in the 7MM
• Total Chemotherapy-induced Peripheral Neuropathy Incident Population
• Chemotherapy-induced Peripheral Neuropathy Severity-specific Incident Population
• Chemotherapy-induced Peripheral Neuropathy Incident Population by Chemotherapeutic Agents
• Chemotherapy-induced Peripheral Neuropathy Incident Population by Cancer Type

Download the report to understand which factors are driving Chemotherapy-induced Peripheral Neuropathy Epidemiology trends @ Chemotherapy-induced Peripheral Neuropathy Prevalence- https://www.delveinsight.com/sample-request/cipn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chemotherapy Induced Peripheral Neuropathy Emerging Drugs Profile

• HALNEURON (tetrodotoxin or TTX): WEX Pharmaceuticals
Tetrodotoxin (TTX) blocks the voltage-gated sodium channels (VGSCs) found on nerves that conduct pain impulses, which are known to be affected in chronic pain conditions. Halneuron is an injectable formulation of tetrodotoxin, a novel small molecule with action on the peripheral nervous system. WEX is in process of launching its pivotal Phase III trial for Halneuron to treat CINP.

• ATX01: AlgoTx
ATX01 is a first-in-class topical treatment for peripheral neuropathic pain. Its development focus is on the pain of CIPN and erythromelalgia. ATX01's pharmacological paradigm targets the epidermis and dermis where the damaged nerve fibers sit and avoids significant systemic absorption and its cascade of side effects. The drug is in Phase II currently and In June 2022, the US FDA granted Fast Track Designation (FTD) to ATX01 for the treatment of CIPN.

Chemotherapy-induced Peripheral Neuropathy Treatment Landscape
Preventive Chemotherapy Induced Peripheral Neuropathy treatments aim to reduce CIPN occurrence or severity during neurotoxic treatments. These Chemotherapy Induced Peripheral Neuropathy medications need to lessen nerve damage without affecting the cancer treatment's ability to fight tumors. While early studies in animals show that cancer-fighting abilities are preserved, large human studies are needed to confirm this. However, trials with different treatments, like drugs and vitamins, face difficulties in how they're set up. The absence of a consistent method to measure nerve damage in these trials contributes to the lack of approved drugs on the market.
Explore the dynamics of the Chemotherapy Induced Diarrhea Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Chemotherapy Induced Diarrhea Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/cipn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chemotherapy Induced Diarrhea Companies
Egetis Therapeutics, MediciNova, Sonnet Biotherapeutics, MakScientific, MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma, Enveric Biosciences, Regenacy Pharmaceuticals, NeuroBo Pharmaceuticals and others

Chemotherapy Induced Diarrhea Market Outlook
The report's outlook on the Chemotherapy Induced Diarrhea market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Chemotherapy Induced Diarrhea therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Chemotherapy Induced Diarrhea drug and late-stage pipeline therapy.

Chemotherapy Induced Diarrhea Drugs Uptake
The drug chapter of the Chemotherapy Induced Diarrhea report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Chemotherapy Induced Diarrhea.

To learn more about Chemotherapy-induced Peripheral Neuropathy treatment guidelines, visit @ Chemotherapy-induced Peripheral Neuropathy Treatment Market Landscape- https://www.delveinsight.com/sample-request/cipn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chemotherapy-induced Peripheral Neuropathy Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Chemotherapy-induced Peripheral Neuropathy Companies- Egetis Therapeutics, MediciNova, Sonnet Biotherapeutics, MakScientific, MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma, Enveric Biosciences, Regenacy Pharmaceuticals, NeuroBo Pharmaceuticals and others.
• Chemotherapy Induced Peripheral Neuropathy Therapies- PledOx, Ibudilast, SON 080, AM 1710 and others.
• Chemotherapy-induced Peripheral Neuropathy Market Dynamics: Chemotherapy-induced Peripheral Neuropathy Market Drivers and Barriers
• Chemotherapy-induced Peripheral Neuropathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Chemotherapy-induced Peripheral Neuropathy Drugs in development @ Chemotherapy-induced Peripheral Neuropathy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/cipn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Executive Summary
3. Chemotherapy Induced Peripheral Neuropathy Competitive Intelligence Analysis
4. Chemotherapy Induced Peripheral Neuropathy Market Overview at a Glance
5. Chemotherapy Induced Peripheral Neuropathy Disease Background and Overview
6. Chemotherapy Induced Peripheral Neuropathy Patient Journey
7. Chemotherapy Induced Peripheral Neuropathy Epidemiology and Patient Population
8. Chemotherapy Induced Peripheral Neuropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Chemotherapy Induced Peripheral Neuropathy Unmet Needs
10. Key Endpoints of Chemotherapy Induced Peripheral Neuropathy Treatment
11. Chemotherapy Induced Peripheral Neuropathy Marketed Products
12. Chemotherapy Induced Peripheral Neuropathy Emerging Therapies
13. Chemotherapy Induced Peripheral Neuropathy Seven Major Market Analysis
14. Attribute Analysis
15. Chemotherapy Induced Peripheral Neuropathy Market Outlook (7 major markets)
16. Chemotherapy Induced Peripheral Neuropathy Access and Reimbursement Overview
17. KOL Views on the Chemotherapy Induced Peripheral Neuropathy Market
18. Chemotherapy Induced Peripheral Neuropathy Market Drivers
19. Chemotherapy Induced Peripheral Neuropathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

List of Top Selling Market Research Reports in 2025

Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac Implantable Electronic Devices Market- https://www.delveinsight.com/report-store/implantable-cardiac-monitors-market
Sleep Tech Devices Market- https://www.delveinsight.com/report-store/sleep-tech-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Urea Cycle Disorders Market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
Testicular Neoplasm Market- https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.